Prioritising phosphatidylethanol to aid classification and treatment of steatotic liver disease
- 11 September 2025
- journal article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 10 (11) , 964-965
Abstract
No abstract availableFunding Information
- National Institute on Alcohol Abuse and Alcoholism
This publication has 9 references indexed in Scilit:
- Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort studyThe Lancet Gastroenterology & Hepatology, 2025
- Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific TreatmentsClinical Gastroenterology and Hepatology, 2025
- Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With CirrhosisClinical Gastroenterology and Hepatology, 2024
- Is there a safe limit for consumption of alcohol?Journal of Hepatology, 2024
- Making the best use of testing for blood phosphatidylethanolLiver Transplantation, 2023
- “But I didn’t drink!”: What to do with discordant phosphatidylethanol resultsLiver Transplantation, 2023
- A multisociety Delphi consensus statement on new fatty liver disease nomenclatureHepatology, 2023
- Alcohol‐related liver disease mortality and missed opportunities in secondary care: A United Kingdom retrospective observational studyDrug and Alcohol Review, 2022
- The stigma of alcohol-related liver disease and its impact on healthcareJournal of Hepatology, 2022